Combined therapy using BCL2 inhibitors and standard chemotherapy has potential to eradicate a clone of human AML cells that exhibits drug resistance, identifiable by high expression of BCL2 and TRIB2. The gene discussed is BCL2; the disease is acute myeloid leukemia.